| Literature DB >> 33443161 |
Joshua J Yim1, Stefan Harmsen2,3, Krzysztof Flisikowski4, Tatiana Flisikowska4, Hong Namkoong5, Megan Garland6, Nynke S van den Berg7, José G Vilches-Moure8, Angelika Schnieke4, Dieter Saur9,10,11, Sarah Glasl12,13, Dimitris Gorpas12,13, Aida Habtezion5, Vasilis Ntziachristos12,13, Christopher H Contag14, Sanjiv S Gambhir2,15,16,17, Matthew Bogyo18,19,20, Stephan Rogalla21,5.
Abstract
Fluorescence imaging is currently being actively developed for surgical guidance; however, it remains underutilized for diagnostic and endoscopic surveillance of incipient colorectal cancer in high-risk patients. Here we demonstrate the utility and potential for clinical translation of a fluorescently labeled cathepsin-activated chemical probe to highlight gastrointestinal lesions. This probe stays optically dark until it is activated by proteases produced by tumor-associated macrophages and accumulates within the lesions, enabling their detection using an endoscope outfitted with a fluorescence detector. We evaluated the probe in multiple murine models and a human-scale porcine model of gastrointestinal carcinogenesis. The probe provides fluorescence-guided surveillance of gastrointestinal lesions and augments histopathological analysis by highlighting areas of dysplasia as small as 400 µm, which were visibly discernible with significant tumor-to-background ratios, even in tissues with a background of severe inflammation and ulceration. Given these results, we anticipate that this probe will enable sensitive fluorescence-guided biopsies, even in the presence of highly inflamed colorectal tissue, which will improve early diagnosis to prevent gastrointestinal cancers.Entities:
Keywords: activity-based probe; early detection; endoscopy; fluorescence; high-risk patients
Mesh:
Substances:
Year: 2021 PMID: 33443161 PMCID: PMC7817203 DOI: 10.1073/pnas.2008072118
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205